Expanding Access to Massage Therapy Could Save the U.S. Healthcare System $11.1 Billion Annually

An AMTA-commissioned economic analysis estimates that broader public and private insurance coverage for massage therapy could generate $11.1 billion in annual U.S. healthcare savings, including $4.0 billion for Medicare and Medicaid. The report also projects $5.6 billion in additional worker earnings, $4.0 billion in added federal, state and local tax revenue, and up to 96,000 additional massage therapists over time. The estimates are conditional on expanded coverage and are advocacy research rather than a confirmed policy change.

Analysis

This is advocacy-sponsored economic modeling rather than a reimbursement decision, so it has no near-term earnings read-through for listed healthcare companies. The central gating variable is not clinical adoption but whether CMS, state Medicaid programs, and commercial payers create reimbursable codes and medical-necessity criteria; that process typically takes years and faces evidence-review, utilization-management, and budget-neutrality constraints.

If coverage advances, the first economic effect is likely higher utilization rather than immediate system savings. Managed-care organizations could face a modest medical-cost headwind before any offset from fewer imaging, opioid, physical-therapy, or surgery claims becomes measurable; providers will also require credentialing and network capacity, limiting early penetration. This makes the claimed aggregate savings unsuitable as an extrapolation to near-term MCO margins.

The more relevant structural read-through is competitive substitution within non-pharmacologic pain care. Physical-therapy operators and benefit managers could see some low-acuity musculoskeletal visits diverted, while Medicare Advantage plans may selectively add massage-like benefits as a retention tool, funding them through supplemental-benefit design rather than broad fee-for-service coverage. Evidence of a CMS demonstration, CPT coding action, or a large insurer pilot would be the first investable catalyst—not further association research.

Contrarian view: broad insurer adoption is unlikely to be a clean cost-saver because newly insured services often induce demand from patients who previously self-paid or did not seek treatment. For public payers, labor-supply constraints and variable practitioner standards could raise unit costs before substitution benefits emerge. No trade is warranted on this release alone.

Key Decisions for Investors

• No directional position on managed care from this item; maintain existing UNH, HUM, CVS/Aetna, ELV and CNC underwriting assumptions until a payer discloses a covered-benefit pilot with utilization and PMPM cost data.
• Set a 6-18 month regulatory alert for CMS coding, Medicare Advantage supplemental-benefit expansion, or state Medicaid mandates. A formal reimbursement pathway would be incrementally negative for MCO medical-loss-ratio expectations unless accompanied by credible offsets in opioid, imaging, or musculoskeletal claims.
• For any MCO exposure, monitor quarterly medical-cost trend and management commentary on musculoskeletal utilization. A sustained 25-50 bp MLR deterioration tied to new complementary-care benefits, without documented downstream savings, would falsify the cost-savings narrative and justify reassessing long exposure.
• Avoid treating the report as a catalyst for public physical-therapy or wellness names: there is no identified listed pure-play beneficiary, and reimbursement timing, rates, and provider-network economics remain unspecified.